Equities analysts expect that Sesen Bio Inc (NASDAQ:SESN) will report ($0.07) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Sesen Bio’s earnings, with estimates ranging from ($0.08) to ($0.06). Sesen Bio reported earnings of ($0.22) per share during the same quarter last year, which indicates a positive year over year growth rate of 68.2%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, April 3rd.
On average, analysts expect that Sesen Bio will report full year earnings of ($0.39) per share for the current year, with EPS estimates ranging from ($0.41) to ($0.36). For the next year, analysts expect that the company will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.32) to ($0.23). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Sesen Bio.
Sesen Bio (NASDAQ:SESN) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08).
SESN has been the topic of a number of analyst reports. Zacks Investment Research lowered Sesen Bio from a “buy” rating to a “hold” rating in a research report on Thursday, October 18th. Jefferies Financial Group initiated coverage on Sesen Bio in a research report on Monday, July 23rd. They issued a “buy” rating and a $4.00 price target on the stock. Finally, ValuEngine raised Sesen Bio from a “hold” rating to a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Sesen Bio currently has an average rating of “Buy” and an average target price of $3.17.
Hedge funds have recently bought and sold shares of the business. Hikari Power Ltd acquired a new stake in shares of Sesen Bio during the 3rd quarter worth about $141,000. BlackRock Inc. raised its position in shares of Sesen Bio by 5.2% during the 3rd quarter. BlackRock Inc. now owns 1,408,316 shares of the company’s stock worth $3,027,000 after acquiring an additional 69,423 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Sesen Bio during the 2nd quarter worth about $147,000. MYDA Advisors LLC acquired a new stake in shares of Sesen Bio during the 2nd quarter worth about $195,000. Finally, DRW Securities LLC acquired a new stake in shares of Sesen Bio during the 2nd quarter worth about $293,000. 52.09% of the stock is currently owned by institutional investors.
SESN stock traded down $0.07 during mid-day trading on Friday, reaching $1.79. The company had a trading volume of 1,345,685 shares, compared to its average volume of 736,364. The firm has a market capitalization of $118.60 million, a P/E ratio of -1.61 and a beta of 2.88. Sesen Bio has a fifty-two week low of $0.62 and a fifty-two week high of $3.50.
Sesen Bio Company Profile
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Featured Story: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.